Bausch + Lomb Likely to Price IPO at Low End or Below Targeted Range
[ad_1]
© Reuters. Bausch + Lom is most likely to sell IPOs below target range or at low ends – WSJAccording to a Wall Street Journal report, Bausch + Lomb will likely price its IPO below or at the lower end of its target range.
Bausch + Lomb planned to become public for $21-$24 per share. This was according to its recent report. filed S-1A. The lower range could be due to a lack of interest from potential investors or ongoing macro volatility in wider markets.
Bausch Health Companies Inc is IPOing the eye-health company. The parent plans to retain 88.5%-90% of the new public company. It will trade on the NYSE under the symbol BLCO.
BHC used to trade as Valeant Pharmaceuticals. purchasedBausch + Lomb 2013 while Bausch + Lomb was on the rise. Valeant fell to the ground after it was exposed for selling research and developing acquisitions and increasing prices. took on the nameBausch Health is part of its turnaround plans.
Bausch + Lomb’s planned spinoff/IPO was scheduled for August 2020. According to the S-1 Bausch + Lomb had revenue of $3.76 Billion (USD), with a free cash flow in excess of $680 M.
[ad_2]